Predictive factors for sunitinib toxicity in renal cell cancer
Author Information
Author(s): van der Veldt A A M, Boven E, Helgason H H, van Wouwe M, Berkhof J, de Gast G, Mallo H, Tillier C N, van den Eertwegh A J M, Haanen J B A G
Primary Institution: VU University medical center, Amsterdam, The Netherlands
Hypothesis
What factors predict severe toxicity in patients with advanced renal cell cancer treated with sunitinib?
Conclusion
Sunitinib shows clinical benefit in unselected patients with advanced renal cell cancer, but many require dose reductions due to severe toxicity.
Supporting Evidence
- 23% of patients achieved a partial response to sunitinib treatment.
- 50% of patients had stable disease while on treatment.
- 57% of patients required a dose reduction due to adverse events.
- Severe toxicity was correlated with low body surface area, high age, and female gender.
Takeaway
This study looked at patients with kidney cancer taking a medicine called sunitinib. It found that many patients had to take less medicine because of side effects, especially older women and those with smaller body sizes.
Methodology
Patients with advanced renal cell cancer were treated with sunitinib in an expanded access program, and their responses and side effects were monitored.
Potential Biases
Potential bias due to the selective inclusion of patients and the observational nature of the study.
Limitations
The study was limited to patients in an expanded access program, which may not represent the broader population.
Participant Demographics
The study included 82 patients, with a median age of 60 years, 67% male and 33% female.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website